Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2025-06-02 00:00:00 ET · period of report 2025-05-30 · accession 0001628280-25-028902 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-02 | 2025-05-30 | VIR | Sigal Charles Elliott | Dir | A - Grant | $0.00 | +8,000 | 31.8K | +34% | $0 |
| D | 2025-06-02 | 2025-05-30 | VIR | Sigal Charles Elliott | Dir | A - Grant | $0.00 | +16.0K | 16.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-30 | A | A | 8,000 | $0.00 | 31,806 | D | — | — | (F2) The RSUs will vest in full on May 30, 2026. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-05-30 | A | A | 16,000 | $0.00 | 16,000 | D | $4.94 · 2026-05-30 to 2035-05-29 | 16,000 Common Stock | (F4) The shares subject to the stock option will vest and become exercisable in full on May 30, 2026. |